Page last updated: 2024-09-03

bw a1433u and n-formylmethionine leucyl-phenylalanine

bw a1433u has been researched along with n-formylmethionine leucyl-phenylalanine in 1 studies

Compound Research Comparison

Studies
(bw a1433u)
Trials
(bw a1433u)
Recent Studies (post-2010)
(bw a1433u)
Studies
(n-formylmethionine leucyl-phenylalanine)
Trials
(n-formylmethionine leucyl-phenylalanine)
Recent Studies (post-2010) (n-formylmethionine leucyl-phenylalanine)
26006,71653356

Protein Interaction Comparison

ProteinTaxonomybw a1433u (IC50)n-formylmethionine leucyl-phenylalanine (IC50)
fMet-Leu-Phe receptorHomo sapiens (human)0.02

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (100.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Carper, HT; Hewlett, EL; Hylton, JB; Linden, J; Mandell, GL; Sullivan, GW1

Other Studies

1 other study(ies) available for bw a1433u and n-formylmethionine leucyl-phenylalanine

ArticleYear
Adenosine and related compounds counteract tumor necrosis factor-alpha inhibition of neutrophil migration: implication of a novel cyclic AMP-independent action on the cell surface.
    Journal of immunology (Baltimore, Md. : 1950), 1990, Sep-01, Volume: 145, Issue:5

    Topics: Actins; Adenosine; Adenosine Deaminase; Cell Movement; Chemotaxis, Leukocyte; Cyclic AMP; Humans; In Vitro Techniques; N-Formylmethionine Leucyl-Phenylalanine; Pentoxifylline; Receptors, Purinergic; Recombinant Proteins; Tumor Necrosis Factor-alpha; Xanthines

1990